Azacitidine–venetoclax improved event-free survival in induction-eligible AML
1. In this randomized phase 2 trial involving previously untreated adults with acute myeloid leukemia, azacitidine–venetoclax improved event-free survival compared ...
1. In this randomized phase 2 trial involving previously untreated adults with acute myeloid leukemia, azacitidine–venetoclax improved event-free survival compared ...
Click here to read this study in The Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. Compared to placebo and azacytidine, the combination of ivosidenib and azacitidine demonstrated significant clinical benefit for IDH1-mutated acute myeloid ...
Image: PD 1. Adding entinostat to azacitidine (AZA) therapy for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with myelodysplasia-related ...
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Monthly plan selected: $4.99 /month.
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free · only $4.16/month
Then $49.90/year. Manage renewal in your account.
Already a member? Sign in